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The aim of this study was to evaluate the expression ofmatrixmetalloproteinase 2 (MMP-2) andmatrixmetalloproteinase 9 (MMP-
9) in prostate cancer in themain tumormass and tumor cells at the positivemargin aswell as the influence of these biomarkers on the
biochemical recurrence of the disease in prostatectomypatients. Tissuemicroarrays of 120 archival prostate carcinoma sampleswere
immunohistochemically evaluated forMMP-2 andMMP-9 expression and compared with clinicopathological parameters. Tumors
with positive surgical margins showed significantly higher overall expression of MMP-9 versus tumors with negative resection
margins (𝑃 = 0.0121). MMP-9 expression was significantly elevated in tumors from patients who had biochemical recurrence
(𝑃 = 0.0207). In the group of patients with negativemargins,MMP-9 expression above the cut-off value was significantly associated
with recurrence (𝑃 = 0.0065). Multivariate analysis indicated thatMMP-9 is a good predictor of biochemical recurrence (odds ratio
= 10.29; 𝑃 = 0.0052). Expression of MMP-2 in tumor cells was significantly higher at the positive margins than in the main tumor
mass (𝑃 = 0.0301). The present results highlight the potential value of MMP-2 and MMP-9 expression for predicting the behavior
of prostate tumors after prostatectomy with both positive and negative surgical margins.
1. Introduction
Extensive studies of the matrix metalloproteinases (MMPs)
indicate that a large number of MMP family factors play
active roles in carcinogenesis and metastasis [1–3]. Many
studies have focused on the role ofMMPs and their inhibitors
in the prognoses of various types of malignancies. Most
published data on MMP-2 and MMP-9 address the role of
these proteins in encouraging the aggressiveness of cancers.
Increased expression of MMP-2 correlates with low survival
in patients with breast cancer [4–8], is associated with a 4.5-
fold higher relative risk of mortality from skin melanoma,
and predicts the risk of metastasis in uveal melanoma [9, 10].
Increased expression of MMP-2 is a sign of poor prognosis
in cancer of the stomach and pancreas [11–13] as well as the
prostate [14].
Kuvaja et al. concluded that low levels of serum pro-
MMP-2 correlate with aggressive cancer behavior [15]. High
MMP-2 expression in hematological malignancies suggests
good prognosis; in contrast, high MMP-9 expression is a
sign of poor disease outcome [16]. The function of MMP-9
is still controversial in solid tumors. Scorilas et al. proposed
that MMP-9 immunoreactive protein can be a favorable sign
for node-negative breast cancer [17]. On the other hand,
investigations of high MMP-9 levels in plasma or serum
samples showed that MMP-9 expression may be associ-
ated with increased risk of recurrence and poor prognosis
[18, 19]. In prostate carcinoma, MMP-2 and MMP-9 are
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novel molecular biomarkers that reflect the invasive and
metastatic potential of this type of carcinoma [20]. The
standard biomarkers that significantly predict the clinical and
biochemical recurrence of prostate cancer are preoperative
serum prostate-specific antigen (PSA), pathological grade
according to Gleason score, positive surgical margins (with
and without extraprostatic extension), and capsular incision
adding up the following factors as of prognostic significance:
presence of perineural, angiolymphatic, seminal vesicle inva-
sion and extraprostatic tissue invasion. However, the real
prognostic importance of positive margins remains to be
defined. Few studies have emphasized the behavior of the
previously mentioned biomarkers on the positive edge of the
resection in comparison to their behavior in the bulk tumor
mass. Recently, Cao et al. addressed the issue of positive
resectionmargins in radical prostatectomy and found that the
Gleason score at the edge of the tumor resection is predictive
of biochemical recurrence [21].There are currently no studies
on the predictive value of MMP expression on the edge of the
resection in radical prostatectomy.
The aim of this study was tomeasure the expression levels
of MMP-2 andMMP-9 in themain tumormass and in tumor
cells on the positive margin and to compare these expression
levels with Gleason score and tumor size in patients treated
by radical prostatectomy. We also examined the influence of
these biomarkers on biochemical recurrence of the disease in
prostatectomy patients.
2. Methods
2.1. Patients. During the period from 2001 to 2006, aci-
nar adenocarcinoma was discovered by ultrasound-guided
biopsy of the prostate in 793 patients at the Clinic of Urol-
ogy, Clinical Hospital Center Rijeka, Croatia. In accordance
with the criteria from the European Urological Association,
candidates for radical prostatectomy had a Gleason score
of 7 or less, PSA levels below 10 ng/mL, and clinically
confirmed prostate cancer in stage T1c/T2c (normal pre-
operative computed tomography findings and pelvic bone
scintigraphy) [22]. From 2001 to 2006, 120 patients who
had undergone radical prostatectomy were chosen from
medical documentation files and adequate clinical data were
collected. Two groups of patients were formed: a group of 71
patients having tumors with negative surgical margins and a
second group of 49 patients with tumors showing positive
surgical margins. Tumor material, obtained from radical
prostatectomy, was selected for the construction of tissue
microarrays. Representative areas on the hematoxylin and
eosin-stained sections were carefully selected and marked on
the corresponding paraffin blocks. From each carcinoma, two
tissue cores (1mm in diameter) were obtained from the main
tumor mass and two cores were taken from the tumor at
the positive surgical margin; these samples were arrayed in a
recipient paraffinblock usingMTABoosterOIManual Tissue
Arrayer (Alphalyse, Plaisir, France).
2.2. Immunohistochemistry. Immunohistochemical staining
for MMP-2 (17B11 mouse monoclonal antibody, Vision
Biosystems Novocastra, Newcastle, UK) and MMP-9 (17W2
Table 1: Clinical and pathological features of patients with prostate
cancer treated with prostatectomy.
Feature
Age of patients (years, median) 64.12
Preoperative serum PSA (ng/mL, median) 8.50











Negative margin group 31.2
Positive margin group 22.6
mouse monoclonal antibody NCL-MMP-9-493, Vision
Biosystems Novocastra) was carried out with an automated
immunostainer (OptiMax Plus, BioGenex) employing a
standard biotin-streptavidin method. Heat-induced pre-
treatment for antigen retrieval (slides were immersed in
a 10mM citrated buffer, pH 6.0, at 95∘C for 5min) was
carried out prior to incubation with primary antibody; the
Dako En/Vision+/HRP Kit was used to visualize MMP
expression. Intestinal tissue of patients with inflammatory
bowel disease (as recommended by the manufacturer) and
the positive control for MMP-9 were normal liver tissues (as
recommended by the manufacturer).
The expression level of each protein was determined with
image analysis system ISSA 3.1 software (Zagreb, Croatia).
Staining was evaluated as the percentage of cytoplasmic-
positive tumor cells multiplied by the staining intensity; this
value was expressed as a histoscore. Clinicopathological data
obtained from patient medical records included age, tumor
size, TNM stage, Gleason score, and margin status of the
prostatectomy specimens (Table 1). We separately examined
the immunoexpression of the MMPs relative to localization
within the tumor mass (MMP expression on the positive
surgical margins and in the bulk of the tumor mass).
3. Results
We found a mean Gleason score significantly higher in the
group with positive surgical margins than in the group with
negative surgical margins (𝑃 = 0.0032; Figure 1).
Immunohistochemical staining against MMP-2 and
MMP-9 in glands with hyperplastic epithelium indicated
weak or negative expression of these proteins, except
for glands with high-grade PIN, where the expression was
stronger (Figures 1). MMP-2 andMMP-9 immunoexpression
in tumor cells was cytoplasmic, finely granular, and varied in
intensity and percentage. We did not find tumors that were
negative for the expression of these proteins (Figures 1).
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Table 2: Expression of MMP-2 and MMP-9 in the main tumor mass and on the resection margin.
𝑁 Average 𝑃
MMP-2
Tumor 95 98.9160 0.0301
Margin 43 109.0237
Tumor mass, positive surgical margin 43 91.3581 0.1833
Tumor mass, negative surgical margin 52 105.1658
MMP-9
Tumor 106 142.1780 0.1214
Margin 45 171.0924
Tumor mass, positive surgical margin 45 157.2962 0.0121























Gleason score 5–7 Gleason score 8–10
P = 0.6965 P = 0.0709
Figure 1: Analysis of Gleason score in patients with positive or
negative surgical margins.
MMP-2 was expressed not only in the cytoplasm of
tumor cells but also in the cytoplasm of prostatic stro-
mal cells, endothelium, fibroblasts, smooth muscle cells,
macrophages, and lymphocytes. The average histoscore of
MMP-2 expression per tumor was 98.9160 (standard devia-
tion (SD) 50.1750). MMP-2 was significantly more strongly
expressed in tumor cells on the positive margins than in the
main tumor mass, with an average of 109.0237 (SD 64.0751;
𝑃 = 0.0301). In the stroma, the strongest MMP-2 expression
occurred in the cytoplasm of inflammatory cells, especially
macrophages (Figure 3).
MMP-9 expression was detected in the cytoplasm of
tumor cells, while stromal cells were weakly positive for
this marker; staining could be categorized as cytoplasmic
or nuclear plus cytoplasmic. The cytoplasm of some tumors
contained more pronounced luminal expression of MMP-9,
while, in other tumors, this staining was diffuse or mostly
peripheral. The average amount of MMP-9 immunostaining
was higher than that of MMP-2 in both examined locations.
The mean MMP-9 expression was 142.1780 (SD 51.0358)
in the main tumor mass and 171.0924 (SD 61.9203) at
the positive margin of resection. Although there was no
significant difference inMMP-9 immunoexpression between
the main tumor mass and the edge, a group of tumors
Table 3: MMP-2 and MMP-9 expression in terms of total Gleason
score and tumor stage and size.
Average histoscore 𝑃
MMP-2 expression in margin
Gleason <7 98.103 0.7417
Gleason ≥7 127.453
Stage 2 113.390 0.5867
Stage 3 102.089
MMP-2 expression in tumor
Gleason <7 99.121 0.9389
Gleason ≥7 98.146
Stage 2 94.942 0.1712
Stage 3 110.771
Size ≤1 cm 114.165 0.5207
Size >1 cm 97.342
MMP-9 expression in margin
Gleason <7 173.391 0.7417
Gleason ≥7 166.927
Stage 2 173.116 0.9093
Stage 3 170.875
MMP-9 expression in tumor
Gleason <7 139.472 0.2597
Gleason ≥7 153.812
Stage 2 137.432 0.1044
Stage 3 155.930
Size ≤1 cm 95.000 0.0378
Size >1 cm 143.067
with positive surgical margins showed significantly stronger
overall expression of MMP-9 compared to a group of tumors
with negative resection margins (𝑃 = 0.0121; Table 2).
Increased expression of MMP-2 and MMP-9 was found
in tumors of better differentiation and higher Gleason score
but with no significant differences between tumors with
Gleason score <7 and high-grade cancers with Gleason score
≥7. Regarding disease stage, MMP-2 staining was slightly
stronger in higher-stage tumors but without statistical signif-
icance. Tumor size was significantly associated with MMP-9
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Table 4: ROC analysis.
AUC 95% confidence interval 𝑃
MMP-2, margin All 0.589 0.413 to 0.749 0.3596
MMP-2, tumor mass
All 0.524 0.408 to 0.638 0.7610
Negative margin 0.525 0.352 to 0.694 0.8108
Positive margin 0.693 0.532 to 0.826 0.0988
MMP-9, margin All 0.551 0.379 to 0.715 0.6352
MMP-9, tumor mass
All 0.626 0.515 to 0.728 0.0582
Negative margin 0.513 0.343 to 0.680 0.8970
Positive margin 0.714 0.567 to 0.834 0.0274
Table 5: MMP-2 and MMP-9 expression and recurrence regarding cut-off values determined by the Youden index.
Youden index 95% CI Associated criterion Sensitivity 95% CI Specificity 95% CI
MMP-2 all margins 0.2609 0.1405 to 0.3344 >52.5 100.00 75.3 to 100.0 26.09 10.2 to 48.4
MMP-2 TM
all 0.1679 0.1203 to 0.1839 >158.33 23.81 8.2 to 47.2 92.98 83.0 to 98.1
neg. margin 0.2475 0.1605 to 0.2910 ≤90 76.92 46.2 to 95.0 47.83 26.8 to 69.4
pos. margin 0.3456 0.1471 to 0.4632 >90 87.50 47.3 to 99.7 47.06 29.8 to 64.9
MMP-9 all margins 0.1827 0.1314 to 0.189 ≤115 30.77 9.1 to 61.4 87.50 67.6 to 97.3
MMP-9 TM
all 0.2553 0.1242 to 0.3941 >141.67 65.22 42.7 to 83.6 60.32 47.2 to 72.4
neg. margin 0.1731 0.1314 to 0.1795 >195 7.69 0.2 to 36.0 75.00 53.3 to 90.2
pos. margin 0.3974 0.1729 to 0.5718 >175 50.00 18.7 to 81.3 89.74 75.8 to 97.1





















Figure 2: Biochemical recurrence with respect to molecular
biomarkers in patients with tumors with negative surgical margins.
expression, which was high in tumors larger than 1 cm (𝑃 =
0.038; Table 3).
We analyzed the biochemical recurrence of the disease
in relation to MMP expression in the group of patients with
negative surgical margins that did not receive any therapy
after prostatectomy that could have affected the outcome.
MMP-9 expression was significantly elevated in tumors from
patients who experienced biochemical recurrence (𝑃 =
0.0207). MMP-2 expression in tumors tended to be increased
in patients with biochemical recurrence (𝑃 = 0.0770;
Figure 2).
We used a receiver operating characteristic (ROC) anal-
ysis, which is widely recognized as a measure of a diagnostic
test’s discriminatory power. The maximum value for the area
under the curve (AUC) is 1.0, indicating a (theoretically)
perfect test (100% sensitive and 100% specific). An AUC
value of 0.5 indicates no discriminative value. We evaluated
MMP-2 and MMP-9 expression as predictors of recurrence
in patients with tumors with negative surgical margins.
MMP-9 expression was detected in all patients (Table 4).
Furthermore, cut-off values for these parameters and groups
were determined based on the Youden index (Table 5).
Analysis of the proportions of patients with and without
recurrence in terms of increasedMMP-9 expression revealed
significant differences between the two groups at a signifi-
cance level of 0.1 (𝑃 = 0.0635).
In the group of patients with negative margins, increased
MMP-9 expression above the cut-off value of 175 was
significantly associated with recurrence (𝑃 = 0.0065), while
MMP-2 expression was not (Table 6).
Univariate and multivariate analysis showed that MMP-
9 expression is a good predictor of biochemical recurrence
(Table 7).
Recurrence-free survival was not significantly shorter in
the group of patients with tumors with negative margins
and high MMP-9 expression (Kaplan-Meier analysis, 𝑃 =
0.5555).
4. Discussion
Prostate diseases are often present in the older population.
Benign enlargement or inflammation of the prostate affect
quality of life, while prostate cancer can be life threatening.
Unfortunately, the routine diagnostic triad of a combination
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(a) (b)
(c) (d)
Figure 3: (a) Glands lined with hyperplastic epithelium and PIN (hematoxylin and eosin staining, 100x). (b) MMP-2 and MMP-9
immunohistochemistry indicates weak or negative expression in hyperplastic epithelium, except for the PIN, where the expression is strong
(100x). (c) MMP-9 immunoexpression in moderately differentiated prostate cancer. Note the intense staining in the cytoplasm of tumor cells
and the strongly positive reaction in the cytoplasm of stromal cells (200x). (d) MMP-2 immunoexpression in poorly differentiated prostate
cancer. Note the strong cytoplasmic staining intensity (200x).
Table 6: MMP-2 and MMP-9 expression in terms of cut-off value
in tumors with negative margins.
Tumors with negative margins Recurrence
N Yes No
MMP-9, tumor margin 0 (≤175) 35 (90%) 5 (10%) 39
1 (>175) 4 (44%) 5 (56%) 9
𝑃 0.0065
MMP-2, tumor margin 0 (≤90) 16 (94%) 1 (6%) 17
1 (>90) 18 (72%) 7 (28%) 25
𝑃 0.1674
of an abnormal PSA level, digital rectal examination, and
transrectal sonography-guided biopsy of the prostate does
not always result in detection of the tumor (sensitivity 75%,
specificity 68%). If one or more tests are abnormal, prostate
biopsy must be performed to confirm or exclude malignant
disease. For now, the best information about limitations,
disease stage, and the malignant potential of the prostate
cancer are obtained by histopathological examination.
Pathological classification of prostate cancer after radical
prostatectomy provides important prognostic information,
and an accurate histopathological report is thought to be
fundamental for treating and monitoring patients. Preop-
erative serum PSA levels, pathological grade according to
Gleason score, invasion into the seminal vesicle, positive
surgical margins with and without extraprostatic extension,
and capsular incision are significant predictors of clinical and
biochemical recurrence. The real prognostic significance of
positive margins and capsule incision remains to be defined
[23, 24].
Approximately 5–43% of patients with radical prostate-
ctomy have positive surgical margins, and only 25–47% of
them develop biochemical recurrence [25]. These observa-
tions suggest the utility of further subclassification of positive
margins in order to identify patients with higher risks of
recurrence. In our study, the overall rate of positive surgical
margins was 29.8% in pT3 tumors and up to 90% in other
tumors, which is similar to other studies [26–28].
The time to recurrence, regardless of treatment, was
significantly shorter in patients with locally confined tumors
with positive surgical margins. This observation is consistent
with the results of Bostwick et al., who reported a positive
impact of positive prostatectomy margins on biochemical
recurrence of the disease [29]. Few studies have emphasized
the potential utilities of biomarker expression on positive
surgical margins relative to the main tumor mass. In our
study, which used tissue microarrays, the average Gleason
score was significantly higher in the group of patients with
tumors with positivemargins, partially confirming the results
of Cao et al. [30].There was no significant difference between
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Table 7: Analysis of the significance of MMP-9 expression for predicting biochemical recurrence.
Univariate analysis Multivariate analysis
OR 95% CI 𝑃 OR 95% CI 𝑃
MMP-2, TM 6.2222 0.6888 to 56.2057 0.1035 5.1721 0.4924 to 54.3318 0.1708
MMP-9, TM 8.7500 1.7411 to 43.9746 0.0078 10.2909 1.6284 to 65.0367 0.0132
𝑃 = 0.0052
OR: odds ratio; CI: confidence interval; and TM: tumor mass.
the average Gleason score on the margins of the tumor
resection and the average Gleason score in the main tumor
mass; this observation may be due to the strict selection of
patients for prostatectomy, which usually requires Gleason
scores ≤7.
The human family of MMPs consists of at least 24 pro-
teinases involved in degradation of the extracellular matrix
and components of the basement membrane. The MMPs are
directly involved in the essential cellular processes of prolif-
eration, differentiation, angiogenesis, and apoptosis through
their ability to catalyze the hydrolysis of various substrates,
including the precursors of cytokines, growth factors, and
hormone receptors. A number of studies revealed positive
correlations between tumor invasion and the activities of the
gelatinases MMP-2 and MMP-9. Expression of these MMPs
is most frequently associated with tumor aggressiveness and
overall survival, and they are used as markers of malignant
phenotypes [31–33].
In prostate cancer, MMP-2 and MMP-9 expression indi-
cate the tumor’s invasive and metastatic potential [34]. Given
the development of specificMMP inhibitors, we assumed that
the immunohistochemical determination of the expression
of these two MMPs would be of particular importance for
therapy, especially if it indicated whether the tumor was at
high risk of recurrence. In our study, we sought to determine
whether MMP-2 and/or MMP-9 expression differed between
aggressive cancers on the positivemargin of the resection that
progress and cancers that remain localized. We detected a
significant difference in MMP-2 expression on the positive
margin versus that in the main tumor mass (𝑃 = 0.0301).
MMP-9 expression at the margin of the resection did not
significantly differ from the expression in the main tumor
mass, but, in the group of tumors with positive margins,
MMP-9 was significantly more strongly expressed overall
versus the group of tumors with negative resection margins
(𝑃 = 0.0121).
In the group of tumors with negative surgical margins,
MMP-9 expression was significantly higher in samples from
patients with biochemical recurrence of the disease. There-
fore, this study yielded additional insight into the potential
value of the biomarkers investigated here, particularly, the
utility of MMP-2 and MMP-9 expression for predicting the
invasive behavior of the tumor and justification for therapy.
This utility has been highlighted by numerous works that
have explored the expression of MMP-2 and MMP-9 in
serum, urine, and tissues from prostate cancers. Sauer and
colleagues linked higher expression of MMP-2 and MMP-9
in serum and tissues with higher Gleason scores [34]. In
our study, MMP-2 and MMP-9 were expressed in tumors
with poor differentiation and higher Gleason scores, but
there were no significant differences between low Gleason
score (<7) and high-grade cancer (Gleason score >7). These
enzymes also displayed significantly higher values in the
serum of metastatic carcinoma. In patients with pT3 tumors,
increased expression of MMP-2 and MMP-9 was associated
with shorter disease-free survival periods; the expression
levels of these markers exhibited statistical significance in
predicting recurrence. Significant decreases in the levels of
these two markers in the sera of patients with metastatic
disease after therapy are useful as independent predictors of
disease stage in combination with the expression of adhesion
molecules [35].
5. Conclusion
The results of this study underscore the potential value of the
expression levels of MMP-2 and MMP-9 for predicting the
invasive behavior of tumors with positive surgical margins;
further investigation of this observation and its utility is
warranted. In our patients with tumors with negative surgical
margins, increasedMMP-9 expression above the cut-off value
was a good predictor of biochemical recurrence, whereas
MMP-2 expression was associated with an increased risk of
relapse.
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